Marissa D. Zwan

Marissa D. Zwan

Auto-generated profile, based on publicly available information

Marissa D. Zwan

Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Neurology, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2019 in JMIR Formative Research
Verified
Journal Article
Open access
IMIngrid S van Maurik
Ingrid S van Maurik
LVLeonie Nc Visser
Leonie Nc Visser
RPRuth E Pel-Littel
Ruth E Pel-Littel
MBMarieke M van Buchem
Marieke M van Buchem
MZMarissa D Zwan
Marissa D Zwan
WFWiesje M van der Flier
Wiesje M van der Flier
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: As a result of advances in diagnostic testing in the field of Alzheimer’s Disease (AD), patients are diagnosed in earlier stages of the disease; for example in the stage of mild cognitive impairment (MCI). This poses novel challenges for the clinician during the diagnostic work-up with regard to diagnostic testing itself (which tests), but also how to engage patients in this decision and how to communicate test results. To this background, tools to support decision making and improve risk communication could be valuable for clinicians and patients. Objective: To describe the development of an online tool for clinicians in a memory clinic setting, that: 1) facilitates the interpretation of biomarker results in individual patients with MCI regarding their risk of progression to dementia, 2) supports clinicians in communicating biomarker test results and risks to MCI patients and their caregivers, and 3) supports clinicians in a process of shared decision-making regarding the diagnostic work-up of AD. Methods: A multi-phase, mixed-methods approach was used: phase 1) qualitative needs assessment among professionals, patients and caregivers, phase 2) iterative process of development and design of the tool (ADappt), and phase 3) quantitative and qualitative assessment of usability and acceptability of ADappt. Across these phases, co-creation was realized via a user-centered, qualitative approach with clinicians, patients and caregivers. Results: In phase 1, clinicians indicated the need for risk calculation tools and visual aids to communicate test results to patients. Patients and caregivers expressed their needs for more specific information on their risk for developing AD and related consequences. In phase 2, we developed the content and graphical design of ADappt encompassing three modules: a risk calculation tool, a risk communication tool including a summary sheet for patients and caregivers, and a conversation starter to support shared decision making regarding the diagnostic work-up. In phase 3, ADappt was considered to be clear and user friendly. Conclusions: This study presents ADappt, an online tool, developed in a multi-phase design characterized by co-creation, that supports clinicians in a memory clinic setting with individually tailored interpretation of biomarker test results, communication of test results and risks to patients and their caregivers, and shared decision making on diagnostic testing.

1 January 2021 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
PDF file
MZMarissa D. Zwan
Marissa D. Zwan
WFWiesje M. van der Flier
Wiesje M. van der Flier
SCSolange Cleutjens
Solange Cleutjens
TSTamara C Schouten
Tamara C Schouten
LVLisa Vermunt
Lisa Vermunt
NPNiels D. Prins
Niels D. Prins
Introduction: The Dutch Brain Research Registry aims to facilitate online recruitment of participants for brain disease studies. Methods: Registrants were primarily recruited through an online social media campaign. The registration process included a short questionnaire, which was subsequently used in the prescreening process to match participants to studies. Results: In the first 18 months, 17,218 registrants signed up (58±11 years old, 78% female). Out of 34,696 study invitations that were sent, 36% were accepted by registrants, of which 50% to 84% were finally enrolled, resulting in 10,661 participants in 28 studies. Compared to non‐participants, study participants were more often older, male, more highly educated, retired or unemployed, non‐smoking, healthier, and more often had a family member with dementia. Discussion: The Dutch Brain Research Registry facilitates effective matching of participants to brain disease studies. Participant factors related to study enrollment may reflect facilitators or barriers for participation, which is useful for improving recruitment strategies.

31 August 2019 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
AFAgnetha D. Fruijtier
Agnetha D. Fruijtier
LVLeonie N. C. Visser
Leonie N. C. Visser
IMIngrid S. van Maurik
Ingrid S. van Maurik
MZMarissa D. Zwan
Marissa D. Zwan
FBFemke H. Bouwman
Femke H. Bouwman
ESEllen M.A. Smets
Ellen M.A. Smets
Information given to patients and caregivers during the clinician-patient encounter varies considerably between memory clinic professionals. Patients and caregivers express a clear desire for more information. It is unclear what information patients and caregivers value most during the diagnostic process and whether this is concordant with professionals’ opinion. We aimed to identify a topic list on which health care professionals, patients, and caregivers agree that these should be discussed during diagnostic consultations in memory clinics. Further, we aimed to establish the optimal moment for each topic to be discussed during the diagnostic process. We performed a three-round Delphi consensus study. Professionals (N = 80), patients (N = 66), and caregivers (N = 76) rated the importance of 44 informative topics through an online questionnaire. Consensus was defined as a topic rating of 6 or 7 on a 7-point Likert scale by ≥ 75% of each panel. In round 2 and 3, a survey was added to identify the optimal moment during the diagnostic process to discuss each topic. By round 3, consensus was achieved on 17 topics divided into four categories, information about (1) diagnostic testing, (2) test results, (3) diagnosis, and (4) practical implications. Eight additional topics showed significant differences between panels. Most notable panel differences regard the risk for developing dementia and the distinction between Alzheimer’s disease and dementia, which patients and caregivers evaluated as more important compared to professionals. The optimal moment to discuss topics during the diagnostic process was identified for the 17 core topics, and the eight topics with significant differences. We present a core list of informative topics, which professionals, patients, and caregivers agree they should be discussed during the diagnostic process in a memory clinic. The topic list can support professionals and empower patients and caregivers during diagnostic physician-patient consultations.

6 January 2020 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
FCFor The Imi-Epad Collaborators
For The Imi-Epad Collaborators
LVLisa Vermunt
Lisa Vermunt
GMGraciela Muniz-Terrera
Graciela Muniz-Terrera
LMLea ter Meulen
Lea ter Meulen
CVColin Veal
Colin Veal
PVPieter Jelle Visser
Pieter Jelle Visser
Background: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in individuals without dementia, especially among cognitively unimpaired. Prescreening on AD risk factors may facilitate recruitment, but the efficiency will depend on how these factors link to participation rates and AD pathology. We investigated whether common AD-related factors predict trial-ready cohort participation and amyloid status across different prescreen settings.Methods: We monitored the prescreening in four cohorts linked to the European Prevention of Alzheimer Dementia (EPAD) Registry (n = 16,877; mean ± SD age = 64 ± 8 years). These included a clinical cohort, a research in-person cohort, a research online cohort, and a population-based cohort. Individuals were asked to participate in the EPAD longitudinal cohort study (EPAD-LCS), which serves as a trial-ready cohort for secondary prevention trials. Amyloid positivity was measured in cerebrospinal fluid as part of the EPAD-LCS assessment. We calculated participation rates and numbers needed to prescreen (NNPS) per participant that was amyloid-positive. We tested if age, sex, education level,APOEstatus, family history for dementia, memory complaints or memory scores, previously collected in these cohorts, could predict participation and amyloid status.Results: A total of 2595 participants were contacted for participation in the EPAD-LCS. Participation rates varied by setting between 3 and 59%. The NNPS were 6.9 (clinical cohort), 7.5 (research in-person cohort), 8.4 (research online cohort), and 88.5 (population-based cohort). Participation in the EPAD-LCS (n = 413 (16%)) was associated with lower age (odds ratio (OR) age = 0.97 [0.95–0.99]), high education (OR = 1.64 [1.23–2.17]), male sex (OR = 1.56 [1.19–2.04]), and positive family history of dementia (OR = 1.66 [1.19–2.31]). Among participants in the EPAD-LCS, amyloid positivity (33%) was associated with higher age (OR = 1.06 [1.02–1.10]) andAPOEɛ4 allele carriership (OR = 2.99 [1.81–4.94]). These results were similar across prescreen settings.Conclusions: Numbers needed to prescreen varied greatly between settings. Understanding how common AD risk factors link to study participation and amyloid positivity is informative for recruitment strategy of studies on secondary prevention of AD.

2 June 2022 in Frontiers in Psychiatry
Verified
Journal Article
Open access
LWLisa Waterink
Lisa Waterink
EBEls D. Bakker
Els D. Bakker
LVLeonie N. C. Visser
Leonie N. C. Visser
FMFrancesca Mangialasche
Francesca Mangialasche
MKMiia Kivipelto
Miia Kivipelto
MZMarissa D. Zwan
Marissa D. Zwan
Background: The COVID-19 pandemic has major influence on lifestyle and mental health, which might affect brain-health and increase the risk of cognitive decline, particularly in older adults. We aimed to describe changes in modifiable risk factors related to brain-health in older adults after one year of COVID-19 restrictions.Methods: An online survey was disseminated between February and March 2021 to 17,773 registrants of the Dutch Brain Research Registry, aged ≥50, without a self-reported diagnosis of mild cognitive impairment or dementia. Participants were asked to report potential changes in behaviors during the COVID-19 pandemic, compared to pre-pandemic, in eight domains related to brain health: physical activity, sleep, feeling of memory decline, perceived stress, feeling of loneliness, diet, alcohol consumption, and smoking. We used negative binomial regression analyses to relate (socio)demographics, subjective memory complaints and COVID-19 related aspects (fear of, or current/past COVID-19 infection) to the number of reported detrimental and beneficial changes as dependent variable.Results: 3,943 participants (66 ± 8 years old; 76% female; 71% highly educated) completed the survey. After one year of COVID-19-restrictions, 74% reported at least one detrimental lifestyle change unfavorable for their brain health, most frequently reported were feelings of loneliness, sleep problems, and less physical activity. 60% of participants reported at least one beneficial change, which were most often more physical activity, healthier dietary habits, and less alcohol consumption. Individuals who are younger [incidence rate ratio (IRR) = 0.99, 95% CI = 0.98–0.99], female (1.20, 1.11–1.30), living alone (1.20, 1.11–1.28) and in urban environments (1.18, 1.08–1.29), who are less satisfied with their income (1.38, 1.17–1.62), experiencing subjective memory complaints (1.40, 1.28–1.52) and those with a past or current (1.19, 1.06–1.34) or fear of a COVID-19 infection (1.33, 1.25–1.42) reported higher numbers of detrimental changes.Discussion: The COVID-19 pandemic has influenced lifestyle in both positive and negative ways. We identified (socio)demographic factors associated with more detrimental changes in modifiable risk factors related to brain health, suggesting that some individuals are more vulnerable for the impact of the COVID-19 pandemic. These findings provide an opportunity for targeted prevention and education to promote a healthy lifestyle during and after the pandemic.

11 December 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
MLMark R. van Loenen
Mark R. van Loenen
LRLianne B. Remie
Lianne B. Remie
MTMara van Trijp
Mara van Trijp
MJMichelle G. Jansen
Michelle G. Jansen
JMJosé P. Marques
José P. Marques
EAEsther Aarts
Esther Aarts
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Studies of multidomain lifestyle interventions show mixed results on preventing or delaying cognitive decline in ageing. A better understanding of the mechanisms underlying these interventions could help explain these mixed findings. Objective: The HELI study aims to investigate the brain and peripheral mechanisms of a multidomain lifestyle intervention in older adults at risk of cognitive decline. Methods: The HELI study is a 6-month multicentre, randomized, controlled multidomain lifestyle intervention trial powered to include 104 Dutch older adults at risk of cognitive decline. Individuals were deemed at risk when scoring ≥2 points on a lifestyle-modifiable risk factor scale (e.g. overweight, physical inactivity, hypertension, hypercholesterolemia). The multidomain lifestyle intervention consisted of five domains (diet, physical activity, stress management/mindfulness, cognitive training, and sleep) and participants were randomized in one of two intervention groups: (1) a high-intensity coaching group consisting of weekly supervised online and on-site group meetings, exercises and learning materials from lifestyle-specific course modules, and (2) a low-intensity coaching group consisting of general lifestyle-related health information sent through e-mail every two weeks. The primary study outcomes are changes between baseline and 6-month follow-up in (1) brain activation in dorsolateral prefrontal cortex (dlPFC) and hippocampus and task accuracy during an fMRI working memory task (2) ASL-quantified cerebral blood flow in dlPFC and hippocampus, (3) systemic inflammation from blood plasma (IL-6, TNF-α, hs-CRP) and (4) microbiota profile from faeces (gut microbiome diversity (Shannon and phylogenetic diversity) and richness (Chao1)). In addition, we will investigate intervention-induced gut-immune-brain links by assessing the relation between the effects found in the aforementioned primary brain and gut outcome measures. Secondary study outcomes include (1) structural and neurochemical MRI, (2) anthropometric measurements, (3) neuropsychological test battery scores, (4) lifestyle-domain related measures from questionnaire scores and a smartwatch, and an array of peripheral measures from (5) faecal analysis, (6) blood analysis, and (7) breath analysis. Results: Between April 2022 and October 2023 we have successfully included n = 102 older Dutch adults (mean age: 66.6 (SD: 4.3) years; 65.7% female) with ≥2 lifestyle-modifiable risk factors of cognitive ageing (median risk: 3 (IQR: 2, 3)). The most common self-reported lifestyle-modifiable risk factors of cognitive ageing at baseline were overweight or obesity (74.5%), followed by hypertension (56.9%), hypercholesterolemia (55.9%), and physical inactivity (55.9%). Conclusions: The HELI study aims to enhance our understanding of working mechanisms of multidomain lifestyle interventions through its comprehensive characterization of central and peripheral markers. We intend to achieve this aim by assessing lifestyle intervention-induced changes in functional and structural MRI brain measures, as well as peripheral measures of the gut-immune-brain axis involved in cognitive ageing. Clinical Trial: ClinicalTrials.gov ID NCT05777863 ToetsingOnline.nl filenumber NL78263.091.21